🔗 Share this article

As the United States undertakes unprecedented adjustments to its vaccination schedules, an unexpected name appears unexpectedly: Tracy Beth Høeg, a US-based physician and epidemiologist who first made her name by expressing skepticism about coronavirus vaccines in the pandemic and has zeroed in on potential fatalities after Covid immunization in her short position at the FDA.

Scheduled Overhauls to Childhood Vaccine Program

Public health authorities had intended to unveil major revisions to the childhood vaccine schedule earlier this month, synchronizing the US with Denmark’s vaccine program, sources say – a significant shift that would put the US out of step with much of the world with no evidence for benefit. The planned update has been postponed until the next year.

Instead of Vinay Prasad, Tracy Beth Høeg is scheduled to present at the gathering. She was recently named temporary leader of the FDA’s CDER, the fifth person to lead the office this year.

A New Direction at the FDA

Høeg's temporary position might represent a tighter collaboration between the drug and biologics divisions as Dr. Høeg and Prasad solidify control at the regulatory agency – and it signals a renewed priority upon reevaluating long-standing vaccines at the FDA.

Dr. Høeg has frequently advocated for halting certain childhood vaccine recommendations in the US in order to be more similar to the Danish model, a nation with comprehensive healthcare and a number of inhabitants approximately the size of the state of Wisconsin.

To date public appearances, she has continued to focus on vaccines – traditionally the responsibility of Dr. Prasad, director of the FDA’s CBER – as opposed to medication approval.

Concerns Over Qualifications

Høeg has no apparent experience in drug development, oversight or administrative roles, which has been customary for previous leaders of the CBER. She has been employed at the FDA as a top consultant to the commissioner and CBER since March.

“She doesn’t seem to have any of the qualifications” for leading the drug-regulation department, remarked Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in managing a major agency. She has no expertise in industry regulation.”

Former heads of CBER would “grasp regulatory frameworks and the underlying principles of medication creation”, noted Dr. Janet Woodcock. “Clearly, she has not acquired the kind of background that previous people who ran CBER have had.”

The drug center has an enormous portfolio at the agency, Woodcock emphasized.

“The public just pays attention on the new drug program, but the generic drug division authorizes numerous generic drugs. There’s a biosimilars program, over-the-counter program and more, and every single one have to be looked after,” she noted. “The area you overlook, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a significant management element to the role, which oversees in excess of 5,000 staff members. “It is a enormous management job, if you execute it properly,” she said.

Response and Contentious Programs

Regarding inquiries about Høeg’s fitness for the role and whether this assignment signifies greater collaboration among FDA leaders on vaccines, a press secretary stated that the “inquiries are based on inaccurate presumptions”.

“Her resume aligns with the responsibilities of her position,” the representative stated, pointing to the time Dr. Høeg spent counseling the agency head on “medication safety and oversight research, including predictive safety algorithms and shot safety tracking”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s new priority voucher program, a controversial rapid drug-approval program that reportedly worried her predecessors. “By what process are these drugs being picked for this fast-track system? Who takes the decisions?” Howard asked. “There is a lot of secrecy going on at the agency right now.”

Overall, he remarked, “the agency looks to be trending towards less stringent oversight of all drugs, with the exception of shots.”

Documented History on Vaccines

Regarding vaccines, Høeg has a more established, if troubling, past, Howard have noted. She authored a study using unverified volunteer-provided data to assess the rate of heart inflammation following Covid immunization. She consulted for the Florida top health official Joseph Ladapo, who was said to have changed statistics to indicate COVID-19 vaccinations are riskier than they are.

Part of her “wish list” for the new administration included altering rules for new vaccines and ending “unnecessary” immunizations, she remarked following the vote on a audio program. At the FDA, Dr. Høeg has allegedly suggested excluding teenage boys from getting Covid vaccines.

“She’s an thorough ideologue who starts off with her beliefs and tailors the evidence to retrofit the science in a highly disingenuous, dishonest way,” Howard said.

Gaining Influence and a “Push for Payback”

Dr. Høeg joined fellow contrarians, {like|